Marie-Claude Trachy-Bourget

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Isabelle Paquin, Daniel Delorme, A. Kalita, 2008, Journal of medicinal chemistry.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Sylvain Lefebvre, Daniel Delorme, A. Kalita, 2008, Molecular Cancer Therapeutics.

Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.

Daniel Delorme, O. Moradei, S. Leit, 2002, Journal of medicinal chemistry.

Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.

Daniel Delorme, A. Kalita, M. Robert, 2003, Journal of medicinal chemistry.